The UK-based CRO anticipates that its FY19 earnings results will be “significantly behind current market expectations,” due to increasing competition and pricing pressures.
Outsourcing-Pharma recently conducted a second ‘state of the industry’ survey to gauge views about the current state of the global pharmaceutical outsourcing market and the evolving relationships of those involved.
The global market for in vitro toxicity testing is predicted to reach $8.8bn by 2023 – and demand is expected to increase, driven by new technologies and regulations, says Charles River.
The multi-year project with an unnamed pharmaceutical company will use the macaque monkey as a developmental model for progressive brain disorders and is valued at more than $1m.
Sutro Biopharma and Merck have signed a collaboration and licensing agreement, which will leverage Sutro's proprietary cell-free protein synthesis and site-specific conjugation platforms.
Antoxerene and investor firm Juvenescence have collaborated to form FoxBio Inc., an offshoot focused on small molecule drug discovery for the pathways of ageing.
Cross-industry discussion is expanding from early discovery to post-licensing challenges – as the nexus of innovation and policy improvements is rapidly changing, says DIA executive.
BASi and Seventh Wave Laboratories are joining operations via an asset purchase agreement, through which BASi will lease the CRO's facility in Maryland Heights, MO.
BioIVT adds transporter assay products and services to its ADME-Toxicology portfolio with the acquisition of Optivia Biotechnology – a deal which aligns with the company’s efforts to support drug safety and efficacy, says VP.
